{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T08:59:55Z","timestamp":1713862795798},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1303,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:p> <jats:bold>Background.<\/jats:bold> Because patients who fail to be cured of <jats:italic>H. pylori<\/jats:italic> infection following macrolide or imidazole therapy are difficult to treat, there is a clear need for a reasonably effective and simple second\u2010line treatment regimen. The purpose of these two studies was to evaluate the efficacy of ranitidine bismuth citrate (RBC) plus amoxicillin for the cure of <jats:italic>H. pylori<\/jats:italic> infection and for healing duodenal ulcers and preventing ulcer relapse.<\/jats:p><jats:p> <jats:bold>Materials and Methods.<\/jats:bold> Two identically designed randomized, double\u2010blind, double\u2010dummy studies were conducted in patients with an <jats:italic>H. pylori<\/jats:italic>\u2010associated duodenal ulcer. Patients were treated with either RBC 400 mg bid for 4 weeks plus amoxicillin 500 mg qid for 2 weeks, RBC 400 mg bid for 4 weeks and placebo qid for 2 weeks, placebo bid for 4 weeks and amoxicillin 500 mg qid for 2 weeks, or placebo bid for 4 weeks and placebo qid for 2 weeks. Patients with healed ulcers after 4 weeks of treatment were eligible for entry into a 24\u2010week observation phase for the assessment of <jats:italic>H. pylori<\/jats:italic> status (culture, histology, and CLOtest<jats:sup>TM<\/jats:sup>) and ulcer relapse.<\/jats:p><jats:p> <jats:bold>Results.<\/jats:bold> A total of 229 patients with confirmed <jats:italic>H. pylori<\/jats:italic> infection at baseline were evaluated. Of these, 132 whose ulcers had healed entered the 24\u2010week posttreatment observation phase. The combination of RBC plus amoxicillin resulted in higher <jats:italic>H. pylori<\/jats:italic> cure rates (55%) and higher duodenal ulcer healing (74%) than did either treatment alone. All treatments were well tolerated.<\/jats:p><jats:p> <jats:bold>Conclusions.<\/jats:bold> The combination of ranitidine bismuth citrate plus amoxicillin cures <jats:italic>H. pylori<\/jats:italic> infection in more than half of the patients treated. This treatment regimen shows promise as the basis for future non\u2010macrolide, non\u2010imidazole triple therapy regimens for curing <jats:italic>H. pylori<\/jats:italic> infection. Such regimens may be appropriate second\u2010line treatment for patients who are resistant to or who are unable to tolerate macrolide\u2010 or imidazole\u2010containing therapies.<\/jats:p>","DOI":"10.1046\/j.1523-5378.1998.08016.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:20:29Z","timestamp":1047424829000},"page":"125-131","source":"Crossref","is-referenced-by-count":6,"title":["An Alternative Non\u2010Macrolide, Non\u2010Imidazole Treatment Regimen for Curing <i>Helicobacter pylori<\/i> and Duodenal Ulcers: Ranitidine Bismuth Citrate Plus Amoxicillin"],"prefix":"10.1111","volume":"3","author":[{"given":"David Y.","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Breiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur A.","family":"Ciociola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"McSorley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"The Rbc Pylori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Study","family":"Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01296437"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-9-705"},{"key":"e_1_2_7_4_2","first-page":"24","article-title":"Helicobacter pylori and duodenal ulcer recurrence","volume":"87","author":"Patchett S","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302043280503"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302043280512"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","article-title":"Helicobacter pylori in peptic ulcer disease\u2014NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease","volume":"272","author":"Soll AH","year":"1994","journal-title":"JAMA"},{"key":"e_1_2_7_8_2","first-page":"76","article-title":"The role of infectious agents in peptic ulcer disease","volume":"6","author":"Tytgat GNJ","year":"1993","journal-title":"Gastroenterol Internat"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90095-G"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01960875"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91043-A"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.192"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.24.10.904"},{"key":"e_1_2_7_14_2","first-page":"1359","article-title":"Nocturnal administration of five antihistamine H2\u2010receptor antagonists: a single\u2010blind comparative study on acid secretion in man","volume":"88","author":"Dammann HG","year":"1985","journal-title":"Gastroenterol"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90929-4"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","unstructured":"Campylobacter pyloriand recurrence of duodenal ulcers\u2014a 12\u2010month follow\u2010up study. Lancet 1987;ii:1109\u201311.","DOI":"10.1016\/S0140-6736(87)91545-5"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104113241507"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003293221307"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198806000-00003"},{"key":"e_1_2_7_20_2","first-page":"A212","article-title":"GR122311X (ranitidine bismuth citrate) with antibiotics for the eradication of Helicobacter pylori (abstract)","volume":"106","author":"Wyeth JW","year":"1994","journal-title":"Gastroenterol"},{"key":"e_1_2_7_21_2","first-page":"497","article-title":"GR122311X (ranitidine bismuth citrate) a new drug for the treatment of duodenal ulcer","volume":"9","author":"Bardhan KD","year":"1995","journal-title":"Gastroenterol"},{"key":"e_1_2_7_22_2","first-page":"A51","article-title":"Safety and pharmacokinetics of ascending oral doses of GR122311X (ranitidine bismuth citrate), a new bismuth compound with anti\u2010secretory properties (abstract)","volume":"102","author":"Ciociola AA","year":"1992","journal-title":"Gastroenterol"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)22868-3"},{"key":"e_1_2_7_24_2","first-page":"A50","article-title":"Safety and pharmacokinetics of chronic oral dosing of GR122311X (ranitidine bismuth citrate), a new bismuth compound with anti\u2010secretory activity (abstract)","volume":"102","author":"Ciociola AA","year":"1992","journal-title":"Gastroenterol"},{"key":"e_1_2_7_25_2","first-page":"1382","article-title":"GR122311X and clarithromycin against Helicobacter (abstract)","volume":"89","author":"McLaren A","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"e_1_2_7_26_2","first-page":"A62","article-title":"GR122311X can significantly reduce the emergence of H. pylori strains resistant to antibiotics (abstract)","volume":"37","author":"McLaren A","year":"1995","journal-title":"Gut"},{"key":"e_1_2_7_27_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/jcm.22.6.1007-1010.1985","article-title":"Characterization of Campylobacter pyloris by culture, enzymatic profile, and protein content","volume":"22","author":"Megraud F","year":"1985","journal-title":"J Clin Microbiol"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1179\/his.1989.12.4.303"},{"key":"e_1_2_7_29_2","first-page":"A105","article-title":"Explanation for variability of omeprazole amoxicillin therapy? Tolerance of H. pylori to amoxicillin (abstract)","volume":"112","author":"Dore MP","year":"1997","journal-title":"Gastroenterol"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1523-5378.1998.08016.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.1998.08016.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1523-5378.1998.08016.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.1998.08016.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:31:37Z","timestamp":1694410297000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1523-5378.1998.08016.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1046\/j.1523-5378.1998.08016.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-5378.1998.08016.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}